Launch Oxylanthanum Carbonate (OLC)
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Nov 2024
- Due
- 31 Dec 2025
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“we are preparing to commercialize and launch OLC in the second half of 2025, if approved.”
What we found
Evidence strength A What the grades mean
The company did not launch OLC in the second half of 2025; as of March 2026, the NDA was still under FDA review with a potential launch date pushed to the third quarter of 2026.
-
A Unicycive Therapeutics, Inc. 8-K filed 2026-03-30
“Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 -Commercial readiness activities ongoing in anticipation of potential commercial launch of OL” ✓ confirmed on the page
Market reaction: the shares moved +8.1% against the S&P 500 over the three sessions around the disclosure (27 Mar 2026 to 1 Apr 2026). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 12 Nov 2024
Deadline 31 Dec 2025 (“in the second half of 2025”)
-
Version 2 · stated 31 Mar 2025
Deadline 31 Dec 2025 (“late 2025”) · wording expected
“Commercial Planning in Preparation for anticipated commercial launch of OLC in late 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Oxylanthanum Carbonate (OLC) commercial launch
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: if approved
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-UNCY-002806 · Corrections policy